臺灣博碩士論文加值系統

本研究建立一簡單、靈敏及快速的毛細管電泳分析法，利用線上濃縮分離技術－電場放大樣品堆積及微胞掃集電動層析法(FASS-sweeping-MEKC)，同時分析人體血清中兩種內生性親蛋白質尿毒素: 硫酸對甲酚(para-cresol sulfate, PCS)及硫酸&;#21554;&;#21722;酚(3-indoxyl sulfate, 3-INS)。以慢性腎衰竭病患而言，由於腎功能的衰退，PCS與3-INS會大量的累積在體內，進而造成許多負面的影響和毒性，在臨床上已漸受重視，故其檢測方法的建立刻不容緩。本法利用含150 mM十二基氫硫酸鈉鹽及10%甲醇之磷酸鹽溶液(100 mM, pH 4.0)作為分析用的緩衝溶液，搭配214 nm的偵測波長，10分鐘內即可完成分離，進行定性與定量分析。血清中PCS與3-INS的偵測極限分別為100及30 ng/mL (S/N=3)。本法之確效結果顯示各待測物在定量範圍內均具有良好的線性關係(r≧0.99)；而在同日內及異日間的精密度與準確度探討，相對標準偏差(RSD)與相對誤差(RE)皆小於3.47%。此外，本研究方法已實際應用於洗腎病患體內尿毒素的分析，期盼在臨床上可協助評估病患疾病嚴重程度及預後之情形，同時也輔助作為投予藥物治療時的客觀性指標。

An efficient, simple, sensitive and rapid on-line sample concentration technique－field-amplified sample stacking-sweeping-micellar electrokinetic chromatography (FASS-sweeping-MEKC) was developed for simultaneous determination of para-cresol sulfate (PCS) and 3-indoxyl sulfate (3-INS) in human serum. PCS and 3-INS are the two important representatives of endogenous “protein-bound uremic toxins” and would accumulate in chronic renal failure patients with impaired kidney functions, leading to various adverse impacts and toxicities on human body. Therefore, detection of PCS and 3-INS are getting more and more attention in recent years at clinic. In this study, qualitative and quantitative analysis of PCS and 3-INS in human serum can be achieved under the optimized conditions. Separation was carried out in phosphate buffer (100 mM, pH 4.0) containing 150 mM SDS and 10% MeOH at 214 nm within 10 min. Detection limit (S/N=3) was found to be 100 ng/mL for PCS and 30 ng/mL for 3-INS. Calibration curves showed great linearity (r≧0.99) and small RSD and RE values (≦3.47%) in intra-day and inter-day assays demonstrated the good precision and accuracy of the CE method. Furthermore, the developed method has been successfully applied to analyze real samples from hemodialysis patients, aiming to be helpful for disease evaluation and become as an objective indicator for medication treatment in patients.

摘要 i
Abstract ii
圖目錄 vi
表目錄 viii
縮寫表 ix
第壹章 緒論 1
第貳章 實驗方法 18
第一節 試藥及材料 18
第二節 主要使用儀器 19
第三節 試藥溶液之配製 21
3.1 儲備溶液之配製 21
3.2 血清檢體的收集與保存 22
3.3 分析用緩衝溶液之配製 22
3.4 建立檢量線之作業溶液 22
3.5 精密度及準確度測試作業之溶液 23
第四節 血清檢體之前處理 23
第五節 毛細管的活化與清洗步驟 23
第六節 毛細管電泳分析條件 24
第七節 血清樣品分析條件之確效 25
7.1 檢量線之建立 25
7.2 分析方法之精密度及準確度 26
7.3 分析方法之絕對與相對回收率 27
第八節 安定性之探討 28
第九節 分析方法之選擇性 29
第參章 結果與討論 30
第一節 血清檢體前處理之探討 30
第二節 FASS-sweeping-MEKC 線上濃縮技術 31
第三節 毛細管電泳分析之條件探討 32
3.1 磷酸鹽緩衝溶液之濃度探討 32
3.2 磷酸鹽緩衝溶液之pH值探討 35
3.3 緩衝液中SDS濃度的探討 37
3.4 緩衝液中甲醇比例(v/v%)的探討 39
第四節 分析方法之確效 40
4.1 偵測極限(LOD)與定量極限(LOQ) 41
4.2 檢量線之建立 42
4.3 精密度及準確度之探討 43
4.4 回收率之探討 45
第五節 安定性之探討 47
5.1 長期安定性 47
5.2 持續性安定性 48
第六節 分析方法之選擇性 49
第七節 應用分析 50
第肆章 結論 53
第伍章 參考文獻 54
人體試驗研究同意證明書 72

[1]National Health Insurance Administration, Ministry of Health and Welfare中華民國衛生福利部中央健康保險署－慢性腎臟病防治(2014)
[2]National Kidney Foundation-Kidney Disease Outcomes Quality Initiative, KDOQI clinical practice guideline for diabetes and chronic kidney disease (2012)
[3]Medscape－Uremia overview (2015), http://emedicine.medscape.co
m/article/245296-overview
[4]鄭文軒：尿毒素硫酸&;#21554;酚之生理病理角色。生物醫學期刊，2，30-39 (2009)
[5]Vanholder R, De Smet R, Glorieux G, Argil&;#233;s A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, J&;#246;rres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W, Review on uremic toxins: classification, concentration, and interindividual variability. Kidney International 63, 1934-1943 (2003)
[6]Vanholder R, Glorieux G, De Smet R, Lameire N, New insights in uremic toxins. Kidney International 63, 6-10 (2003)
[7]Varshney A, Rehan M, Subbarao N, Rabbani G, Khan RH, Elimination of endogenous toxin, creatinine from Blood plasma depends on albumin conformation: site specific uremic toxicity &; impaired drug binding. Public Library of Science ONE 6, 1-15 (2011)
[8]Jonathan H, Urea: surrogate or toxin. Kidney International 56, 754-755 (1999)
[9]Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW, Effects of urea loading in patients with far-advanced renal failure. Mayo Clinic Proceedings 47, 21-29 (1972)
[10]Bergstr&;#246;m J, F&;#252;rst P, Zimmerman L, Uremic middle molecules exist and are biologically active. Clinical nephrology 11, 229-238 (1979)
[11]Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G, Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. Journal of the American Society of Nephrology 17, 546-555 (2006)
[12]Canaud B, Morena M, Cristol JP, Krieter D, Beta2-microglobulin, a uremic toxin with a double meaning. Kidney International 69, 1297-1299 (2006)
[13]Ito S, Yoshida M, Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins 6, 665-678 (2014)
[14]Vanholder R, De Smet R, Lameire N, Protein-bound uremic solutes: the forgotten toxins. Kidney International 78, 266-270 (2001)
[15]Brunet P, Dou L, Cerini C, Berland Y, Protein-bound uremic retention solutes. Advances in Renal Replacement Therapy 10, 310-320 (2003)
[16]Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R, p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology Dialysis Transplantation 22, 592-596 (2007)
[17]Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y, Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney International 69, 1081-1087 (2006)
[18]McGregor D, Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Critical Reviews in Toxicology 37, 887-914 ( 2007)
[19]Igarashi K, Ueda S, Yoshida K, Kashiwagi K, Polyamines in renal failure. Amino Acids 31, 477-483 (2006)
[20]Yoshida K, Yoneda T, Kimura S, Fujimoto K, Okajima E, Hirao Y, Polyamines as an inhibitor on erythropoiesis of hemodialysis patients by in vitro bioassay using the fetal mouse liver assay. Therapeutic apheresis and dialysis 10, 267-272 (2006)
[21]Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J, A bench to bedside view of uremic toxins. Journal of the American Society of Nephrology 19, 863-870 (2008)
[22]Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis Transplantation 20, 1048-1056 (2005)
[23]Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H, Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circulation Research 111, 1470-1483 (2012)
[24]Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH, Serum protein-bound uremic toxins and clinical outcomes in haemodialysis patients. Nephrology Dialysis Transplantation 25, 3693-3700 (2010)
[25]The Human Metabolome Database (HMDB)-Indoxyl sulfate and para-cresol sulfate (2015)
[26]林承叡、吳志仁、陳逸洲、陳漢湘：親蛋白質尿毒素—對甲酚(p-cresol) 的病理生理學角色。生物醫學期刊，1，5-13 (2008)
[27]Rossi M, Campbell KL, Johnson DW, Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. OA Nephrology 13, 2-8 (2013)
[28]Meijers BK, Evenepoel P, The gut–kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrology Dialysis Transplantation 26, 759-761 (2011)
[29]Evenepoel P, Meijers BK, Bammens BR, Verbeke K, Uremic toxins originating from colonic microbial metabolism. Kidney International 76, 12-19 (2009)
[30]Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R, p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology Dialysis Transplantation 22, 592-596 (2007)
[31]Berg&;#233;-Lefranc D, Chaspoul F, Calaf R, Charpiot P, Brunet P, Gallice P, Binding of p-cresylsulfate and p-cresol to human serum albumin studied by microcalorimetry. The Journal of Physical Chemistry B 114, 1661-1665 (2010)
[32]Sakai T, Takadate A, Otagiri M, Characterization of binding site of uremic toxins on human serum albumin. Biological and Pharmaceutical Bulletin 18, 1755-1761 (1995)
[33]Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P, The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International 65, 442-451 (2004)
[34]Jankowski J, Hagemann J, Yoon MS, van der Giet M, Stephan N, Zidek W, Schl&;#252;ter H, Tepel M, Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney International 59, 1134-1141 (2001)
[35]Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, De Smet R, Vanholder R, Sampol J, Berland Y, p-Cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney International 62, 1999-2009 (2002)
[36]Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, De Smet R, Vanholder R, Sampol J, Berland Y, p-Cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thrombosis and Haemostasis 92, 140-150 (2004)
[37]Boelaert J, Lynen F, Glorieux G, Eloot S, Van Landschoot M, Waterloos MA, Sandra P, Vanholder R, A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Analytical and Bioanalytical Chemistry 405, 1937-1947 (2013)
[38]Sun CY, Hsu HH, Wu MS, p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrology Dialysis Transplantation 28, 70-78 (2013)
[39]Kitagawa A, Effects of cresols (o-, m-, and p-isomers) on the bioenergetic system in isolated rat liver mitochondria. Drug and Chemical Toxicology 24, 39-47 (2001)
[40]Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, Noguchi T, Kadowaki D, Ishima Y, Kotani S, Nakajima M, Kataoka K, Kim-Mitsuyama S, Tanaka M, Fukagawa M, Otagiri M, Maruyama T, p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney International 83, 582-592 (2013)
[41]M&;#252;ting D, Studies on the pathogenesis of uremia. Comparative determinations of glucuronic acid, indican, free and bound phenols in the serum, cerebrospinal fluid, and urine of renal diseases with and without uremia. Clinica Chimica Acta 12, 51-54 (1965)
[42]Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman JL, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R, Novel method for simultaneous determination of p-cresyl sulphate and p-cresyl glucuronide: clinical data and pathophysiological implications. Nephrology Dialysis Transplantation 27, 2388-2396 (2012)
[43]Bryan GT, Urinary excretion of indoxyl sulfate (indican) by human subjects ingesting a semisynthetic diet containing variable quantities of L-tryptophan. The American Society for Clinical Nutrition 19, 113-119 (1966)
[44]Smith EA, Macfarlane GT, Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Microbial Ecology 33, 180-188 (1997)
[45]Patel KP, Luo FJ, Plummer NS, Hostetter TH, Meyer TW, The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clinical Journal of the American Society of Nephrology 7, 982-988 (2012)
[46]Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW, Colonic contribution to uremic solutes. Journal of the American Society of Nephrology 22, 1769-1776 (2011)
[47]Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B, Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. Biopharmaceutics &; Drug Disposition 34, 165-175 (2013)
[48]Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T, Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-κB. BioMed Central Nephrology 14, 1-9 (2013)
[49]Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P, The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. Journal of Thrombosis and Haemostasis 5, 1302-1308 (2007)
[50]Niwa T, Ise M, Miyazaki T, Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. American Journal of Nephrology 14, 207-212 (1994)
[51]Shimizu H, Bolati D, Higashiyama Y, Nishijima F, Shimizu K, Niwa T, Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-κB, p53, ERK, and JNK in proximal tubular cells. Life Sciences 90, 525-530 (2012)
[52]Shimizu H, Yisireyili M, Nishijima F, Niwa T, Indoxyl sulfate enhances p53-TGF-β1-Smad3 pathway in proximal tubular cells. American Journal of Nephrology 37, 97-103 (2013)
[53]Miyazaki T, Ise M, Seo H, Niwa T, Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney International 62, 15-22 (1997)
[54]Adelibieke Y, Shimizu H, Muteliefu G, Bolati D, Niwa T, Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity. Journal of Renal Nutrition 22, 86-89 (2012)
[55]Bowmer CJ, Lindup WE, Decreased drug binding in uremia: effect of indoxyl sulfate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochemical Pharmacology 31, 319-323 (1982)
[56]Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E, Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney International 69, 1780-1785 (2006)
[57]Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P, The uremic retention solute p-cresyl sulfate and markers of endothelial damage. American Journal of Kidney Diseases 54, 891-901(2009)
[58]Taki K, Tsuruta Y, Niwa T, Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. American Journal of Nephrology 27, 30-35 (2007)
[59]Hsu CC, Lu YC, Chiu CA, Yu TH, Hung WC, Wang CP, Lu LF, Chung FM, Lee YJ, Tsai IT, Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis. Clinical &; Investigative Medicine 36, 42-49 (2013)
[60]Yu M, Kim YJ, Kang DH, Indoxyl sulfate–induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clinical Journal of the American Society of Nephrology 6, 30-39 (2011)
[61]Kim YH, Kwak KA, Gil HW1, Song HY, Hong SY, Indoxyl sulfate promotes apoptosis in cultured osteoblast cells. BioMed Central Pharmacology and Toxicology 14, 1-9 (2013)
[62]Barreto FC, Barreto DV, Canziani ME, Tomiyama C, Higa A, Mozar A, Glorieux G, Vanholder R, Massy Z, de Carvalho AB, Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. The Jornal Brasileiro de Nefrologia 36, 289-296 (2014)
[63]Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T, Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrology Dialysis Transplantation 23, 1892-1901 (2008)
[64]Mozar A, Louvet L, Godin C, Mentaverri R, Brazier M, Kamel S, Massy ZA, Indoxyl sulphate inhibits osteoclast differentiation and function. Nephrology Dialysis Transplantation 27, 2176-2181 (2012)
[65]Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T, Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrology Dialysis Transplantation 24, 2051-2058 (2009)
[66]Cheng JL, Chih KC, Thanasekaran J, Hsuan LL, Chi FP, Tuen JW, Han HC, Chih JW, Serum concentration of p-cresol and indoxyl sulfate in elderly hemodialysis patients. International Journal of Gerontology 5, 80-83 (2011)
[67]Niwa T, Uremic toxicity of indoxyl sulfate. Nagoya Journal of Medical Science 72, 1-11 (2010)
[68]Kiss I, The uremic toxin, indoxyl sulfate, signifies cardio-renal risk and intestinal-renal relationship. Orvosi Hetilap 152, 1724-1730 (2011)
[69]Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H, Cardiorenal syndrome: role of protein-bound uremic toxins. Journal of Renal Nutrition 25, 149-154 (2015)
[70]Niwa T, Takeda N, Tatematsu A, Maeda K, Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid Chromatography. Clinical Chemistry 34, 2264-2267 (1988)
[71]Calaf R, Cerini C, G&;#233;nov&;#233;sio C, Verhaeghe P, Jourde-Chiche N, Berg&;#233;-Lefranc D, Gondouin B, Dou L, Morange S, Argil&;#233;s A, Rathelot P, Dignat-George F, Brunet P, Charpiot P, Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. Journal of Chromatography B 879, 2281-2286 (2011)
[72]Takeda N, Niwa T, Maeda K, Shibata M, Tatematsu A, Rapid assay for indoxyl sulphate in uremic serum by internal-surface reversed-phase high-performance liquid chromatography. Journal of Chromatography 431, 418-423 (1988)
[73]Al Za''abi M, Ali B, Al Toubi M, HPLC–fluorescence method for measurement of the uremic toxin indoxyl sulfate in plasma. Journal of Chromatographic Science 51, 40-43 (2013)
[74]De Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, Evenepoel P, Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. Journal of Chromatography A 1216, 4684-4688 (2009)
[75]Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, Alton KB, Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicology and Applied Pharmacology 255, 48-56 (2011)
[76]Cuoghi A, Caiazzo M, Bellei E, Monari E, Bergamini S, Palladino G, Ozben T, Tomasi A, Quantification of p-cresol sulphate in human plasma by selected reaction monitoring. Analytical and Bioanalytical Chemistry 404, 2097-2104 (2012)
[77]De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K, Gas chromatographic–mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clinical Chemistry 51, 1535-1538 (2005)
[78]亞旭生物科技股份有限公司ASIA BIOSCIENCE CORPORATION, Antibodies-online.com－Indoxyl sulfate ELISA Kit
[79]Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, Wu CJ, p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. Journal of Clinical Laboratory Analysis 25, 191-197 (2011)
[80]Chen FT, Liu CM, Hsieh YZ, Sternberg JC, Capillary electrophoresis-a new clinical tool. Clinical Chemistry 37, 14-19 (1991)
[81]Petersen JR, Okorodudu AO, Mohammad A, Payne DA, Capillary electrophoresis and its application in the clinical laboratory. Clinica Chimica Acta 330, 1-30 (2003)
[82]Chen G, Wang J, Fast and simple sample introduction for capillary electrophoresis microsystems. Analyst 129, 507-511 (2004)
[83]Altria K, Marsh A, S&;#228;nger-van de Griend C, Capillary electrophoresis for the analysis of small-molecule pharmaceuticals. Electrophoresis 27, 2263-2282 (2006)
[84]Smith A, Nelson RJ, Capillary electrophoresis of DNA. Current protocols in nucleic acid chemistry, Chapter 10:Unit 10.9 (2003)
[85]Kitagawa F, Otsuka K, Recent applications of on-line sample preconcentration techniques in capillary electrophoresis. Journal of Chromatography A 1335, 43-60 (2014)
[86]Long YH, Hernandez M, Kaale E, Van Schepdael A, Roets E, Borrull F, Calull M, Hoogmartens J, Determination of kanamycin in serum by solid-phase extraction, pre-capillary derivatization and capillary electrophoresis. Journal of Chromatography B 784, 255-264 (2003)
[87]Schulman G, Vanholder R, Niwa T, AST-120 for the management of progression of chronic kidney disease. International Journal of Nephrology and Renovascular Disease 7, 49-56 (2014)
[88]Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M, Randomized placebo-controlled EPPIC trials of AST-120 in CKD. Journal of the American Society of Nephrology 26, 1-15 (2014)
[89]Maeda K, Hamada C, Hayashi T, Shou I, Wakabayashi M, Fukui M, Horikoshi S, Tomino Y, Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. The Journal of International Medical Research 37, 205-213 (2009)
[90]Hatakeyama S, Yamamoto H, Okamoto A, Imanishi K, Tokui N, Okamoto T, Suzuki Y, Sugiyama N, Imai A, Kudo S, Yoneyama T, Hashimoto Y, Koie T, Kaminura N, Saitoh H, Funyu T, Ohyama C, Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. International Journal of Nephrology 2012, 1-8 (2012)
[91]Guidance for industry, bioanalytical method validation. U.S. department of health and human services, food and drug administration (2013)